Uji Diagnostik Genexpert MTB/RIF Di Rumah Sakit Umum Pusat Haji Adam Malik Medan

  

DAFTAR PUSTAKA

Accumedia, Lowentein - Jensen medium (7245). PI 7245.2010: Rev 05.

  Available a Accesed: 19 September 2014.

  Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012;9. Albert H, Bwanga F, Mukkada S et al. Rapid screening of MDR-TB using molecular Line Probe Assay is feasible in Uganda. BMC Infectious

  Disease . 2010;10(41).

  Banada PP, Sivasubramani SK, Blakemore R, et al. Contaiment of bioaerosol infection risk by the Xpert MTB/RIF assay and its applicabilityto point-of- care settings. J. Clin. Microbiol. 2010;48:3551-3557. Battaglioli T, Rintiswati N, Martin A, et al. Comparative performance of Thin Layer Agar and Lowenstein-Jensen culture for diagnosis of tuberculosis.

  Clinical Microbiology and Infection . 2013;19(11):502-508.

  Blakemore R, Story E, Helb D, Kop J, et al. Evaluation of the analytical performance of the Xpert MTB/RIF assay. J Clin Microbiol.

  2010;48(7):2495-2501.

  TM

  Boehme C. Study protocol-Xpert MTB/RIF demonstration-feasibility, impact and cost-efficiency of decentralizing molecular testing for detection of

  TM tuberculosis and rifampicin rsistance using Xper MTB/RIF. FIND, 2009.

  Boehme CC, Nabeta P, Hilleman, et al. Rapid molecular detection of tuberculosis and rifampisin resistance. N Eng J Med. 2010;363:1005-1015. Boulware DR. Utility of the Xpert MTB/RIF assay for diagnosis of tuberculosis meningitis. PLoS Med. 2013;10(10). Brito RC, Mello FCQ, Andrade MK, et al. Drug-resistant tuberculosis in six hospitals in Rio de Janeiro, Brazil. Int J Tuberc Lung Dis. 2010;14(1):24-

  33. Burhan E. Peran ISTC dalam pencegahan MDR. Jurnal Tuberkulosis Indonesia. 2010;7:12-15. Calligaro GL, Moodley L, Symons G, Dheda K. The medical and surgical treatment of drug resistant tuberculosis. J Thorac Dis. 2014;6(3):186-195. Caminero JA. Justification for the guidelines. Dalam: Guidelines for Clinical and

  Operational Management of Drug-Resistant Tuberculosis. International Union Against Tuberculosis and Lung Disease . 2013:1-6. Castan P, Pablo A, Romero A, et al. Point-of-care system for detection of

  Mycobacterium tuberculosis and rifampin resistance in sputum samples. J Clin Microbio . 2014;52(2):502-507. Chiang CY. Basic concepts and definitions of drug resistance in tuberculosis

  Dalam Guidelines for Clinical and Operational Management of Drug- Resistant Tuberculosis. International Union Against Tuberculosis and Lung Disease . 2013:13-25.

  Coovadia YM, Mahomed S, Pillay M, Werner L, Mlisana K. Rifampicin Mono- Resistance in Mycobacterium tuberculosis in KwaZulu-Natal, South Africa: A Significant Phenomenon in a high prevalence TB-HIV region.

  PLoS One . 2013;8(11).

  Da Silva PEA, Palomino JC. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. Antimicrob

  Chemother . 2011;66:1417–1430.

  Direktorat Jenderal Bina Upaya Kesehatan. Petunjuk teknis pemeriksaan biakan, identifikasi, dan uji kepekaan Mycobacterium tuberculosis pada media padat. Kementerian Kesehatan Republik Indonesia. 2012. Available at: http://perpustakaan.depkes.go.id:8180/bitstream//123456789/1796/2/BK20 12-401.pdf . Accesed: 19 Spetember 2014. Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan. Petunjuk teknis manajemen terpadu pengendalian tuberkulosis resistan obat.

  Kementerian Kesehatan Republik Indonesia . 2013:1-86.

  Dlamini-Mvelase NR, Wener R, Phili R, Cele LP, Mlisana P. Effect of introducing Xpert MTB/RIF test on multidrug resistant tuberculosis diagnosis in Kwazulu-Natal South Africa. BMC Infectious Disease. 2014;14(442). Enarson DA, Harries AD. Historical background and global epidemiology of

  Mycobacterium tuberculosis resistance. Dalam: Guidelines for Clinical and Operational Management of Drug-Resistant Tuberculosis.

  International Union Against Tuberculosis and Lung Disease . 2013:7-12.

  Essaway TS, Saeed AM, Fouad NA. Comparative study between using Lowenstein Jensen, Bio-FM media and mycobacteria growth indicator tube (MGIT) system in identification of Mycobacterium tuberculosis.

  

Egyptian Journal of Chest Disease and Tuberculosis . 2014;67(2):377-384.

  Evans CA. GeneXpert—a game-changer for tuberculosis control?. PLoS Med.

  2011;8(7). Friedrich SO, Rachow A, Saathoff E, et al. Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment. Lancet Respir Med. 2013;1(6):462-470. Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug- resistant tuberculosis: a threat to global control of tuberculosis. Lancet.

  2010; 375:1830–43. Hakeem A, Hussain MS , Imran Sarwar MI. GeneXpert MTB/RIF- a novel diagnostic tool for tuberculosis in pulmonary samples. IOSR Journal of

  Dental and Medical Sciences . 2013;8:1-3.

  Halilu TB, Bala Z, Florence S, Yerima IB. Multi-drug resistance tuberculosis (mdr-tb) survey in North East Nigeria. J. Pharm. Cosmet.Sci. 2014;2(1):1- 5.

  Hanafi AR, Prasenohadi. Mekanisme dan diagnosis multidrug resistant tuberculosis. PPTI , 2010. Available at: Accessed: August 17, 2014. Helb D, Jones M, Story E, et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of demand near patient technology. J Clin

  Microbiol . 2010;48(1):229-237.

  Ioannidis P, Papaventsis D, Karabela S, et al. Cepheid GeneXpert MTB/RIF assay for Mycobacterium tuberculosis detection and rifampisisn resistance identification in patiens with substantial clinical indications of tuberculosis and smear-negative microscopy results. J. Clin. Microbiol. 2011;49(8):3068-3070. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis.

  PLoS One . 2009;4.

  Lawn SD, Nicol MP. Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. Future Microbiol. 2011;6(9):1067-82. Lawn SD, Wood R. Tuberculosis in antiretroviral treatment services in resource- limited settings: addressing the challenges of screening and diagnosis. J

  Infect Dis . 2011;204:1159-1167. Liang L, Wu Q, Gao L,et al. Factors contributing to the high prevalence of multidrug-resistant tuberculosis: a study from China. Thorax. 2012;67. Li j, Xin J, Zhang L, Jiang L, Cao H, Li L. Rapid detection of rpoB in rifampin resistant M. tuberculosis from sputum samples by denaturing gradient gel electrophoresis. Int J Med Sci. 2012;9(2):148-156. Low S, Ang LW, Cutter J, et al. Mortality among tuberculosis patients on treatment in Singapore. Int J Tuberc Lung Dis. 2009;13:328-334. Marlowe EM, Novan-Weekley SM, Cumpio J, et al. Evaluation of the Cepheid

  Xpert MTB/RIF assay for direct detection of Mycobacterium tuberculosis complex in respiratory specimens. J. Clin. Microbiol.2011;49(4):1621.

  Menzies D, Benedetti A, Paydar A, et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono- resistance to isoniazid: a systematic review and metaanalysis. PLoS Med. 2009;6(9). Micheletti VCD, Moreira JS, Ribeiro MO, Kritski AL, Braga JU. Drug-resistant tuberculosis in subjects included in the second national survey on antituberculosis drug resistance in Porto Alegre, Brazil. J Bras Pneumol. 2014;40(2):155-163. Migliori GB, D’Arcy Richardson M, Sotgiu G, Lange C. Multidrug-resistant and extensively drug resistant tuberculosis in the West. Europe and United

  States: epidemiology, surveillance, and control. Clin Chest Med. 2009;30:637-665.

  Minh NN, Van Bac N, Son NT et al. Molecular characteristics of rifampin-and isoniazid-resistant Mycobacterium tuberculosis strains isolated in Vietnam. J Clin Microbiol. 2012; 50(3). Minion J, Gallant V, Wolfe J, et al. Multidrug and extensively drug-resistant tuberculosis in Canada 1997–2008: demographic and disease characteristics. PLoS One. 2013;8. Ministry of Health and Family Welfare. Revised national TB control programme training manual for Mycobacterium tuberculosis culture & drug susceptibility test. New Delhi, 2009:5-19. Nathanson E, Nunn P, Uplekar M, et al. MDR tuberculosis — critical steps for prevention and control. N Engl J Med. 2010;363:1050-1058.

  Nawas A. Penatalaksanaan TB MDR dan strategi DOTS plus. Jurnal Tuberkulosis . 2010;7:1-7.

  Indonesia Nofizar D, Nawas A, Burhan E. Identifikasi faktor resiko tuberkulosis multidrug resistant (TB-MDR). Maj Kedokt Indon. 2012;60(12):537-545.

  Nwokoye NN, Onubogu CC, Nwadike OP, et al. Non-conforming rifampicin susceptibility test reports from Xpert MTB/RIF assay: the national reference laboratory experience in Nigeria. Open Science Journal of Clinical Medicine . 2014;2(2);59-62.

  Ocheretina O, Escuyer VE, Mabou MM et al. Correlation between genotypic and phenotypic testing for resistance to rifampin in Mycobacterium

  tuberculosis in clinical isolates in Haiti: investigation of cases with discrepant susceptibility results. PLoS One. 2014:9(3).

  Osman M, Simpson JA, Caldwell J, Bosman M, Nicol MP. GeneXpert MTB/RIF version G4 identification of rifampin-resistant tuberculosis in programmatic setting. J Clin Microbiol. 2014;52(2):635-637. Patel DM, Patel SD, Jaiswal P, Brahmbhatt KJ. Drug resistant Mycobacterium tuberculosis and new drug development. Int. J. Drug Dev. & Res. 2012;

  4(2):76-91. Piatek AS, Cleeff M, Alexander H. GeneXpert for TB diagnosis: planed and purposeful implementation. Global Health Science and Practice. 2013;

  1(1). Pinto L, Menzies D. Treatment of drug-resistant tuberculosis. Infection and Drug Resistance . 2011;4:129-135.

  Pires GM, Folgosa E, Nquobile N, Gitta S, Cadir N. Mycobacterium tuberculosis resistance to antituberculosis drugs in Mozambique. J Bras Pneumol.

  2014; 40(2):142-147. Poli TB MDR RSUP Haji Adam Malik. Laporan TB 03 2012. Medan,2013. Raizada N, Sachdeva KS, Chauhan DS, et al. A multi-site validation in India of the Line Probe Assay for the rapid diagnosis of multi-drug resistant tuberculosis directly from sputum specimens. PLoS One. 2014;9(2). Raj A, Sing N, Metha PK. GeneXpert MTB/RIF assay: a new hope for extrapulmonary tuberculosis. IOSR Journal of Pharmacy. 2012;2(1):083-

  089. Ramirez MV, Cowart CK, Campbell PJ, et al. Rapid detection of multidrug- resistant Mycobacterium tuberculosis by use of real-time PCR and high- resolution melt analysis. J Clin Microbiol. 2010;48(11):4003–4009. Rifat M, Milton AH, Hall J, et al. Development of Multidrug Resistant Tuberculosis in Bangladesh: A Case-Control Study on Risk Factors. PLoS One . 2014; 9(8).

  Sarwani D. Faktor resiko multidrug resistant tuberculosis (MDR-TB). Jurnal Kesehatan Masyarakat . 2012;8(1):60-66. Sharma SK, Kumar S, Saha PK et al. Prevalence of multidrug-resistant tuberculosis among category II pulmonary tuberculosis patients. Indian J

  Med Res. 2011; 133:312-315.

  Sharma R, Yadav R, Sharma M, Saini V, Koushal V. Quality of life of multi drug resistant tuberculosis patients:a study of North India Acta Medica Iranica, 2014;52(6):448-453. Shim TS, Jo KW. Medical treatment of pulmonary multidrug-resistant tuberculosis. Infect Chemother, 2013;45(4):367-374.

  Sihombing H, Sembiring H, Amir Z, Sinaga BYM. Pola resistensi primer pada penderita TB paru kategori I di RSUP H. Adam Malik Medan. J Respir

  Indo . 2012;32(3).

  Sinaga BYM. Karakteristik penderita Multidrug Resistant Tuberculosis yang mengikuti Programmatic Management of Drug-Resistant Tuberculosis di Rumah Sakit Umum Pusat H. Adam Malik Medan. J Respir Indo. 2013;33(4):221-229. Sirait N, Parwati I, Dewi NS, Suraya N. Validitas metode Polymerase Chain

  Reaction GeneXpert MTB/RIF pada bahan pemeriksaan sputum untuk mendiagnosis multidrug resistant tuberculosis. MKB, 2013;45(4):234-239. Sjahrurachman A. Diagnosis multi drug resistant Mycobacterium tuberculosis.

  Jurnal Tuberkulosis Indonesia , 2010;7:8-10.

  Small PM, Pai M. Tuberculosis diagnosis — time for a game change. N Engl J Med. 2010;363:1070-1071. Soepandi PZ. Diagnosis dan faktor yang mempengaruhi terjadinya MDR TB.

  Jurnal Tuberkulosis Indonesia . 2010;7:16-9.

  Steingart KR, Sohn H, Schiller L, et al. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults (review). Cochrane

  Database of Systematic Reviews , 2013;1:1-35.

  Suharmiati, Maryani H. Analisis hubungan penggunaan obat FDC/kombipak pada penderita yang didiagnosis TB paru berdasarkan karakteristik. Buletin

  Penelitian Sistem Kesehatan . 2011;14:167-173. Trébucq A, Enarson DA , Chiang CY, et al. Xpert® MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how?.

  Int J Tuberc Lung Dis . 2011;15(12):1567–1571.

  Van Rie A, Page-Shipp L, Scott L, Sanne I, Stevens W. Xpert® MTB/RIF for point-of care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope?. Expert Rev Mol Diagn. 2010;10(7):937-946. World Health Organization. Automatic real-time nucleic acid amplification technology for rapid and simultaneous detection and rifampicin resistance:

  Xpert MTB/RIF system. Geneva, 2011a (WHO/HTM/TB/2011.4):1-4. World Health Organization. Rapid implementation of the Xpert MTB/RIF diagnostic test. Geneva, 2011b (WHO/HTM/TB/2011.2). Available at whqlibdoc.who.int/publication/2011/9789241501569_eng.pdf. Acessed Januari 21 2015.

  World Health Organization. Drug-resistant tuberculosis. 2012. Available at: ccessed Mei 28 2014. World Health Organization. Global tuberculosis report 2013. Geneva,2013a (WHO/HTM/TB/2013.11):6-67. World Health Organization. Defenition and reporting framework for tuberculosis- 2013 revision. 2013b. World Health Organization. The use of molecular line probe assay for detection of resistance to second-line anti-tuberculosis drug. Expert Group Meeting

  Report . Geneva, 2013c.

  World Health Organization. Tuberculosis diagnostics Xpert MTB/RIF test. 2013d.

  Available a Accesed August 16, 2014.

  World Health Organization. Rapid implementation of the Xpert MTB/ RIF diagnostic test: technical and operational “How-to”, practical consideration, Geneva, 2014. Yadav RN, Singh BK, Sharma SK, et al. Comparative evaluation of GenoType

  MTBDRplus line probe assay with solid culture method in early diagnosis of multidrug resistant tuberculosis (MDR-TB) at a tertiary care centre in India. PLoS One. 2013;8. Yao C, Zhu T, Li Y et al. Detection of rpoB, katG and inhA mutations in

  Mycobacterium tuberculosis in clinical isolates from Chonqing as determined by microarray. Clin Microbiol Infect. 2010;16:1639-1643. Yuan X, Zhang T, Kawakami K, et al. Genotyping and clinical characteristics of multidrug and extensively drug-resistant tuberculosis in a tertiary care tuberculosis hospital in China. BMC Infectious Diseases. 2013;13(315). Zetola NM, Shin SS, Tumedi KA, et al. Mixed Mycobacterium tuberculosis complex infections and false-negative result for rifampin resistance by

  GeneXpert MTB/RIF are associated with poor clinical outcomes. J Clin Microbiol . 2014; 52(7):2422-2429. Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuber Lung Dis . 2009;13(11):1320–1330. Zhao Y, Xu S, Wang L. National survey of drug resistant tuberculosis in China. N Engl J Med . 2012;366:2161-2170. Zumla AI, Raviglione M, Hafner R, Von Reyn CF. Tuberculosis. N. Engl J. Med.

  2013;368:745-75